106 related articles for article (PubMed ID: 20198594)
1. [Caffeine as a preventive drug for Parkinson's disease: epidemiologic evidence and experimental support].
Góngora-Alfaro JL
Rev Neurol; 2010 Feb 16-28; 50(4):221-9. PubMed ID: 20198594
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine.
Góngora-Alfaro JL; Moo-Puc RE; Villanueva-Toledo JR; Alvarez-Cervera FJ; Bata-García JL; Heredia-López FJ; Pineda JC
Neurosci Lett; 2009 Oct; 463(3):210-4. PubMed ID: 19654037
[TBL] [Abstract][Full Text] [Related]
3. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
4. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
[TBL] [Abstract][Full Text] [Related]
5. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.
Ross GW; Petrovitch H
Drugs Aging; 2001; 18(11):797-806. PubMed ID: 11772120
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence.
Joghataie MT; Roghani M; Negahdar F; Hashemi L
Parkinsonism Relat Disord; 2004 Dec; 10(8):465-8. PubMed ID: 15542005
[TBL] [Abstract][Full Text] [Related]
7. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
8. Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats.
Moo-Puc RE; Villanueva-Toledo J; Arankowsky-Sandoval G; Alvarez-Cervera F; Góngora-Alfaro JL
Neurosci Lett; 2004 Sep; 367(3):327-31. PubMed ID: 15337259
[TBL] [Abstract][Full Text] [Related]
9. Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.
Singh S; Singh K; Patel S; Patel DK; Singh C; Nath C; Singh MP
Brain Res; 2008 May; 1207():193-206. PubMed ID: 18374908
[TBL] [Abstract][Full Text] [Related]
10. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
11. Caffeine and risk of Parkinson's disease in a large cohort of men and women.
Palacios N; Gao X; McCullough ML; Schwarzschild MA; Shah R; Gapstur S; Ascherio A
Mov Disord; 2012 Sep; 27(10):1276-82. PubMed ID: 22927157
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
Kurkowska-Jastrzebska I; Litwin T; Joniec I; Ciesielska A; Przybyłkowski A; Członkowski A; Członkowska A
Int Immunopharmacol; 2004 Oct; 4(10-11):1307-18. PubMed ID: 15313429
[TBL] [Abstract][Full Text] [Related]
13. Formation of stacking complexes between caffeine (1,2,3-trimethylxanthine) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may attenuate biological effects of this neurotoxin.
Ulanowska K; Piosik J; Gwizdek-Wiśniewska A; We Grzyn G
Bioorg Chem; 2005 Oct; 33(5):402-13. PubMed ID: 16165186
[TBL] [Abstract][Full Text] [Related]
14. Effects of caffeine on the freezing of gait in Parkinson's disease.
Kitagawa M; Houzen H; Tashiro K
Mov Disord; 2007 Apr; 22(5):710-2. PubMed ID: 17373724
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
Xu K; Bastia E; Schwarzschild M
Pharmacol Ther; 2005 Mar; 105(3):267-310. PubMed ID: 15737407
[TBL] [Abstract][Full Text] [Related]
16. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen.
Ascherio A; Weisskopf MG; O'Reilly EJ; McCullough ML; Calle EE; Rodriguez C; Thun MJ
Am J Epidemiol; 2004 Nov; 160(10):977-84. PubMed ID: 15522854
[TBL] [Abstract][Full Text] [Related]
17. Caffeine and coffee as therapeutics against Alzheimer's disease.
Arendash GW; Cao C
J Alzheimers Dis; 2010; 20 Suppl 1():S117-26. PubMed ID: 20182037
[TBL] [Abstract][Full Text] [Related]
18. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
19. [Medicamentous strategy for improving the quality of life in the senescence].
Knoll J
Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
